PL3972604T3 - Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej - Google Patents
Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznejInfo
- Publication number
- PL3972604T3 PL3972604T3 PL20729204.6T PL20729204T PL3972604T3 PL 3972604 T3 PL3972604 T3 PL 3972604T3 PL 20729204 T PL20729204 T PL 20729204T PL 3972604 T3 PL3972604 T3 PL 3972604T3
- Authority
- PL
- Poland
- Prior art keywords
- bruton
- treatment
- tyrosine kinase
- kinase inhibitor
- chronic spontaneous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851996P | 2019-05-23 | 2019-05-23 | |
| PCT/IB2020/054755 WO2020234782A1 (en) | 2019-05-23 | 2020-05-20 | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3972604T3 true PL3972604T3 (pl) | 2025-09-22 |
Family
ID=70918751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20729204.6T PL3972604T3 (pl) | 2019-05-23 | 2020-05-20 | Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12419889B2 (https=) |
| EP (2) | EP4599894A3 (https=) |
| JP (2) | JP7568651B2 (https=) |
| KR (1) | KR20220012281A (https=) |
| CN (1) | CN113795255A (https=) |
| AU (2) | AU2020280272B2 (https=) |
| BR (1) | BR112021022602A2 (https=) |
| CA (1) | CA3138081A1 (https=) |
| CL (1) | CL2021003032A1 (https=) |
| DK (1) | DK3972604T3 (https=) |
| ES (1) | ES3039974T3 (https=) |
| FI (1) | FI3972604T3 (https=) |
| HR (1) | HRP20251001T1 (https=) |
| IL (1) | IL286983B2 (https=) |
| LT (1) | LT3972604T (https=) |
| MX (2) | MX2021013942A (https=) |
| PL (1) | PL3972604T3 (https=) |
| PT (1) | PT3972604T (https=) |
| RS (1) | RS67141B1 (https=) |
| SI (1) | SI3972604T1 (https=) |
| TW (2) | TW202537625A (https=) |
| WO (1) | WO2020234782A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67141B1 (sr) | 2019-05-23 | 2025-09-30 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije |
| JP7564347B2 (ja) | 2021-09-03 | 2024-10-08 | ノバルティス アーゲー | 多発性硬化症を治療するためのｌｏｕ０６４ |
| US20250032488A1 (en) | 2021-12-14 | 2025-01-30 | Novartis Ag | Methods of treatment using lou064 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| KR102834740B1 (ko) * | 2023-04-10 | 2025-07-17 | 아주대학교산학협력단 | Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물 |
| WO2024235163A1 (zh) * | 2023-05-12 | 2024-11-21 | 武汉人福创新药物研发中心有限公司 | Btk抑制剂的用途和单剂量药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2705719C (en) | 2007-09-14 | 2016-10-11 | Janssen Pharmaceutica N.V. | Thieno-and furo-pyrimidine modulators of the histamine h4 receptor |
| US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3092250A4 (en) | 2014-01-08 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| WO2016079669A1 (en) * | 2014-11-19 | 2016-05-26 | Novartis Ag | Labeled amino pyrimidine derivatives |
| RS67141B1 (sr) | 2019-05-23 | 2025-09-30 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije |
-
2020
- 2020-05-20 RS RS20250816A patent/RS67141B1/sr unknown
- 2020-05-20 AU AU2020280272A patent/AU2020280272B2/en active Active
- 2020-05-20 US US17/612,778 patent/US12419889B2/en active Active
- 2020-05-20 CA CA3138081A patent/CA3138081A1/en active Pending
- 2020-05-20 BR BR112021022602A patent/BR112021022602A2/pt unknown
- 2020-05-20 HR HRP20251001TT patent/HRP20251001T1/hr unknown
- 2020-05-20 LT LTEPPCT/IB2020/054755T patent/LT3972604T/lt unknown
- 2020-05-20 EP EP25178785.9A patent/EP4599894A3/en active Pending
- 2020-05-20 ES ES20729204T patent/ES3039974T3/es active Active
- 2020-05-20 SI SI202030651T patent/SI3972604T1/sl unknown
- 2020-05-20 MX MX2021013942A patent/MX2021013942A/es unknown
- 2020-05-20 PL PL20729204.6T patent/PL3972604T3/pl unknown
- 2020-05-20 JP JP2021568760A patent/JP7568651B2/ja active Active
- 2020-05-20 CN CN202080032000.3A patent/CN113795255A/zh active Pending
- 2020-05-20 IL IL286983A patent/IL286983B2/en unknown
- 2020-05-20 PT PT207292046T patent/PT3972604T/pt unknown
- 2020-05-20 KR KR1020217041089A patent/KR20220012281A/ko not_active Ceased
- 2020-05-20 DK DK20729204.6T patent/DK3972604T3/da active
- 2020-05-20 WO PCT/IB2020/054755 patent/WO2020234782A1/en not_active Ceased
- 2020-05-20 FI FIEP20729204.6T patent/FI3972604T3/fi active
- 2020-05-20 EP EP20729204.6A patent/EP3972604B1/en active Active
- 2020-05-21 TW TW113146310A patent/TW202537625A/zh unknown
- 2020-05-21 TW TW109116854A patent/TWI868139B/zh active
-
2021
- 2021-11-12 MX MX2024014626A patent/MX2024014626A/es unknown
- 2021-11-17 CL CL2021003032A patent/CL2021003032A1/es unknown
-
2024
- 2024-08-21 JP JP2024139784A patent/JP2024178168A/ja active Pending
-
2025
- 2025-08-27 US US19/311,292 patent/US20250375446A1/en active Pending
- 2025-10-17 AU AU2025252618A patent/AU2025252618A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3972604T3 (pl) | Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej | |
| ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| IL287745A (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JOP20200209A1 (ar) | مثبطات cd73 | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| IL261249B1 (en) | Dosage preparations containing Bruton's tyrosine kinase inhibitor | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| EA201791946A1 (ru) | Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk | |
| EA201990226A1 (ru) | Способы и композиции для лечения миелофиброза | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| IL259862B (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| SI3609886T1 (sl) | Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| IL264341A (en) | Succinate forms and preparations of proton tyrosine kinase inhibitors | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
| EP3543239C0 (en) | SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE | |
| IL289758A (en) | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries | |
| IL284916A (en) | Cyclic molecules as Bruton's tyrosine kinase inhibitors | |
| ZA202102274B (en) | Use of casein kinase 1 inhibitors for treating vascular diseases | |
| EP3402468C0 (en) | PI3K P-DELTA 110 INHIBITORS FOR USE IN DELIVERY OF VIRUSES TO TREAT CANCER | |
| PL4072532T3 (pl) | Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie | |
| DK3846788T3 (da) | Pde11-hæmmere til anvendelse i behandling af parkinsons sygdom |